WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 17, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 22, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 14, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 19, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 30, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00am ET on Monday, December 7, 2020 to discuss updated
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 31, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit , MD, Senior Vice President and Chief Medical Officer, is stepping down from her